John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at [email protected].
Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.
Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.
Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.
The vaccine, Jynneos, manufactured by Bavarian Nordic, is being shipped to Africa to address the ongoing mpox outbreak.
Peggy Lillis Foundation CEO Christian Lillis talks about how he became involved in advocacy around C diff and his motivation in helping to bring a bill to Congress to make the healthcare-associated infection a nationally notifiable infectious disease and condition.
With the ongoing war between Israel and Hamas, The World Health Organization reported a public health update. Officials are concerned about what is happening inside the Gaza Strip particularly around a variety of diseases and health conditions including hepatitis A, skin infections, and even polio.
Baby formula manufacturer, Perrigo, issued a voluntary recall due to high levels of vitamin D that were above the maximum level permitted.
Kate Broderick, PhD, molecular geneticist, discusses the mRNA capping technology and how it helps create stability to mRNA molecules within vaccines and guides them to cells.
A large Veterans Health Administration (VA) outpatient study showed a large increase in MRSA resistance in one particular area of the United States and varying antimicrobial resistance patterns overall.
A new phase 1 clinical trial will determine if vaccine candidate, MPV/S-2P, is safe for humans, and may potentially offer protection not seen before in the first-generation of COVID-19 vaccines.
The federal agency says the ongoing outbreak of the clade 1 variant in the Democratic Republic of Congo has been reported in neighboring countries.
In this week’s edition of MMWR, the Centers for Disease Control and Prevention reported on the vaccines’ safety profile for each of the FDA approved immunizations and rationale for the recommended age groups.
The World Health Organization (WHO) warns of a moderate global risk to the presence of the pathogen, hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23, as it has been reported in at least 1 country in all 6 WHO Regions.
A large English study shows the incidence rates of arterial thromboses and venous thrombotic events decreased after immunization.
A Spanish man contracted the virus after a tick bite and succumbed to it last week.
A bill in the House of Representatives was just introduced with the advocacy of the Peggy Lillis Foundation in hopes of bringing more recognition and research to the healthcare-associated infection.
A hospital CDI intervention program that supported patients via an ID specialist demonstrated clinical benefits compared to another hospital where patients were followed by providers of any specialty.
New funding will go towards research around a specific molecule that has been shown to lower inflammation.
A new study looks at the role of genetics in the leveling degrees of infection.
A new analysis says if all states imposed such measures it would have saved thousands of lives.
A secondary analysis of a randomized trial points to limited benefits on the microbiota.
Boar’s Head is recalling its liverwurst product as well as other deli meats due to concerns around contamination.
The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.
A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).
A study finds clinically-relevant sub-phenotypes can be reproducibly, and could lead to patient stratification and treatment.
CDC reports 2 deaths so far, and several more people sickened across multiple states.
Participants of the phase 3 trial for the Pfizer and Valneva vaccine candidate, VLA15, received their immunizations and everyone will be observed through next year’s Lyme disease season.
A large study from the Veterans Affairs shows an association between being unvaccinated and a greater incidence rate of Long COVID.
The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.
